Arrowhead Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good afternoon, everyone. I'm Salveen Richter, a biotechnology analyst at Goldman Sachs. I'm pleased to have with us Arrowhead Therapeutics with Chris Anzalone, CEO.
Questions & Answers
With that, Chris, thanks for joining us. And maybe a question here on your overall portfolio. You've got First data emerging and extrahepatic tissues.
can you just help us understand as you look to go outside the liver, why you chose lung and solid tumors as your first target and where you're going on the Ford there?
Sure. Thanks very much. And thanks for having us. It's really a pleasure to be here, and good afternoon. So look lung wasn't, for us, was a bit of a no-brainer. It's a target-rich environment. There is a number of well-validated targets to go after a number of disease
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |